TxCell Share Price

Stocks

TXCL

FR0010127662

Biotechnology & Medical Research

Real-time 5-day change 1st Jan Change
- EUR -.--% Intraday chart for TxCell -.--% +67.53%
Manager TitleAgeSince
Chief Operating Officer 50 -
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman - 11/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
-4.31%-2.14%+65.79%+103.90% 72.12B
-4.19%+18.35%+52.79%+86.77% 65.85B
-3.22%+23.17%+7.38%-5.23% 29.28B
-1.42%-3.38%-3.38%+465.34% 27.47B
-4.71%+7.67%+47.63%+18.25% 26.7B
-1.81%+4.19%+34.52%-17.69% 20.06B
+5.36%-1.67%+270.18%+415.10% 18.22B
-2.79%+0.48%+12.09%+562.03% 16.4B
+0.87%+4.26%+43.93%+150.80% 13.4B
Average -1.62%+8.55%+58.99%+197.70% 32.17B
Weighted average by Cap. -2.83%+8.78%+55.33%+154.65%
Logo TxCell
TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection. TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.
Employees
-
  1. Stock Market
  2. Stocks
  3. TXCL Stock